The prevalence of KRAS mutation in colorectal cancer patients in Iranian population: A systematic review and meta-analysis study

Authors

  • Mehrdad Payandeh Department of Bone Marrow Transplantation, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
  • Nasrin Amirifard Department of Radiation Oncology, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
  • Masoud Sadeghi Medical Biology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
  • Babak Shazad Department of Internal Medicine, Taleghani Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
  • Negin Farshchian Department of Radiation Oncology, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran
  • Edris Sadeghi Department of Bone Marrow Transplantation, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran; Department of Nursing, Borujerd Branch, Islamic Azad University, Borujerd, Iran http://orcid.org/0000-0001-7742-9372
  • Malihe Dayani Department of Radiation Oncology, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

DOI:

https://doi.org/10.15419/bmrat.v4i10.374

Keywords:

CRC, Iran, KRAS, prevalence, medicine

Abstract

Colorectal cancer (CRC) is one of the most common cancers in the World that KRAS mutations are considered as a key step in the progression of CRC. This meta-analysis study aimed to evaluate the prevalence of KRAS mutations in CRC patients in Iran. Six online databases including PubMed, Science direct, Scopus, Web of science, Cochran Library, and Scientific Information Database (SID) were searched systematically up to January 2017. A random-effects meta-analysis was used to calculate the estimation of the prevalence of KRAS mutations in CRC patients by the event rate (ER) with 95% confidence interval (95%CI). Out of 82 articles identified from the search, eleven studies included and analyzed for meta-analysis study. The studies included 1814 CRC patients that mean age of the patients was 57.5 years. The pooled ER of the studies for estimation of the prevalence of KRAS mutation in CRC patients was 32.8% (95%CI=28.7-37.3%). The pooled ER of the studies for the prevalence of codon 12 mutation was 72.5% (95%CI=59.8-82.3%) and for codon 13 mutation was 20% (95%CI=14.6-26.7%). The results showed that the prevalence of KRAS mutation in Iran was different with more studies that therefore the geographical area and race can impact on the prevalence of KRAS mutation in CRC patients. Also, codon 12 had the most prevalence among mutant codons, followed by codon 13 that Gly to Asp and Gly to Val were the most mutations in codon 12.

 

Author Biography

  • Edris Sadeghi, Department of Bone Marrow Transplantation, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran; Department of Nursing, Borujerd Branch, Islamic Azad University, Borujerd, Iran
    sadeghi_mkn@yahoo.com

References

<ol>
<li class="show">Amirifard, N., Sadeghi, E., Farshchian, N., Haghparast, A., and Choubsaz, M. (2016). Evaluation of KRAS Gene Mutations in Metastatic Colorectal Cancer Patients in Kermanshah Province. Asian Pacific journal of cancer prevention: APJCP 17, 3085-3088.</li>
<li class="show">Bishehsari, F., Mahdavinia, M., Malekzadeh, R., Verginelli, F., Catalano, T., Sotoudeh, M., Bazan, V., Agnese, V., Esposito, D., and De Lellis, L. (2006). Patterns of K-ras mutation in colorectal carcinomas from Iran and Italy (a Gruppo Oncologico dell'Italia Meridionale study): influence of microsatellite instability status and country of origin. Annals of oncology 17, vii91-vii96. <a href="https://doi.org/10.1093/annonc/mdl959 Burt, R.W. (2000)">https://doi.org/10.1093/annonc/mdl959 Burt, R.W. (2000)</a>.</li>
<li class="show">Colon cancer screening. Gastroenterology 119, 837-853. https://doi.org/10.1053/gast.2000.16508 Chretien, A.S., Harlé, A., Meyer‐Lefebvre, M., Rouyer, M., Husson, M., Ramacci, C., Harter, V., Genin, P., Leroux, A., and Merlin, J.L. (2013). Optimization of routine KRAS mutation PCR‐based testing procedure for rational individualized first‐line‐targeted therapy selection in metastatic colorectal cancer. Cancer medicine 2, 11-20.&nbsp;<a href="https://doi.org/10.1002/cam4.47">https://doi.org/10.1002/cam4.47</a></li>
<li class="show">Ciardiello, F., Tejpar, S., Normanno, N., Mercadante, D., Teague, T., Wohlschlegel, B., and Van Cutsem, E. (2011). Uptake of KRAS mutation testing in patients with metastatic colorectal cancer in Europe, Latin America and Asia. Targeted oncology 6, 133.&nbsp;<a href="https://doi.org/10.1007/s11523-011-0181-x">https://doi.org/10.1007/s11523-011-0181-x</a></li>
<li class="show">Dobre, M., Dinu, D.E., Panaitescu, E., Birla, R.D., Iosif, C.-I., Boeriu, M., Constantinoiu, S., Ivan, R.N., Ardeleanu, C.M., and Costache, M. (2015). Kras gene mutations–prognostic factor in colorectal cancer. Rom J Morphol Embryol 56, 671-678.</li>
<li class="show">Dolatkhah, R., Somi, M.H., Kermani, I.A., Bonyadi, M., Sepehri, B., Boostani, K., Azadbakht, S., Fotouhi, N., Farassati, F., and Dastgiri, S. (2016). association between proto-oncogene mutations and clinicopathologic characteristics and overall survival in colorectal cancer in east azerbaijan, iran. OncoTargets and therapy 9, 7385.&nbsp;<a href="https://doi.org/10.2147/OTT.S116373">https://doi.org/10.2147/OTT.S116373</a></li>
<li class="show">El Kader, Y.A., Emera, G., Safwat, E., Kassem, H.A., and Kassem, N.M. (2013). The KRAS StripAssay for detection of KRAS mutation in Egyptian patients with colorectal cancer (CRC): A pilot study. Journal of the Egyptian National Cancer Institute 25, 37-41.&nbsp;<a href="https://doi.org/10.1016/j.jnci.2012.12.003">https://doi.org/10.1016/j.jnci.2012.12.003</a></li>
<li class="show">Fearon, E.R., and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell 61, 759-767. https://doi.org/10.1016/0092-8674(90)90186-I Miglio, U., Mezzapelle, R., Paganotti, A., Allegrini, S., Veggiani, C., Antona, J., Gentilli, S., Monga, G., Alabiso, O., and Boldorini, R. (2013). Mutation analysis of KRAS in primary colorectal cancer and matched metastases by means of highly sensitivity molecular assay. Pathology-Research and Practice 209, 233-236.&nbsp;<a href="https://doi.org/10.1016/j.prp.2013.02.006">https://doi.org/10.1016/j.prp.2013.02.006</a></li>
<li class="show">Naseri, M., Sebzari, A., Haghighi, F., Hajipoor, F., and Razavi, F.E. (2016). Frequency of K-RAS and N-RAS Gene Mutations in Colorectal Cancers in Southeastern Iran. Asian Pacific Journal of Cancer Prevention 17, 4511-4515.</li>
<li class="show">Omidifar, N., Geramizadeh, B., and Mirzai, M. (2015). K-ras mutation in colorectal cancer, a report from southern Iran. Iranian journal of medical sciences 40, 454.</li>
<li class="show">Ozen, F., Ozdemir, S., Zemheri, E., Hacimuto, G., Silan, F., and Ozdemir, O. (2013). The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population. Genetic testing and molecular biomarkers 17, 135-139.&nbsp;<a href="https://doi.org/10.1089/gtmb.2012.0290">https://doi.org/10.1089/gtmb.2012.0290</a></li>
<li class="show">Palmirotta, R., Savonarola, A., Formica, V., Ludovici, G., Del Monte, G., Roselli, M., and Guadagni, F. (2009). A novel K-ras mutation in colorectal cancer. A case report and literature review. Anticancer research 29, 3369-3374.</li>
<li class="show">Payandeh, M., Shazad, B., Sadeghi, M., and Shahbazi, M. (2016). Correlation between RAS test results and prognosis of metastatic colorectal cancer patients: a report from Western Iran. Asian Pac J Cancer Prev 17, 1729-1732.&nbsp;<a href="https://doi.org/10.7314/APJCP.2016.17.4.1729">https://doi.org/10.7314/APJCP.2016.17.4.1729</a></li>
<li class="show">Rosty, C., Young, J.P., Walsh, M.D., Clendenning, M., Walters, R.J., Pearson, S., Pavluk, E., Nagler, B., Pakenas, D., and Jass, J.R. (2013). Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Modern Pathology 26, 825.&nbsp;<a href="https://doi.org/10.1038/modpathol.2012.240">https://doi.org/10.1038/modpathol.2012.240</a></li>
<li class="show">Roudbari, F., Poopak, B., Sheikhsofla, F., and Ghadiani, M. (2016). Evaluation of frequency of kirsten rat sarcoma gene mutations in Iranian colorectal cancer. Tehran University Medical Journal TUMS Publications 74, 392-399.</li>
<li class="show">Selcukbiricik, F., Erdamar, S., Ozkurt, C., Molinas Mandel, N., Demirelli, F., Ozguroglu, M., Tural, D., Buyukunal, E., and Serdengecti, S. (2013). The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer. J BUON 18, 116-123.</li>
<li class="show">Shemirani, A.I., Haghighi, M.M., Milanizadeh, S., Taleghani, M.Y., Fatemi, S.R., Damavand, B., Akbari, Z., and Zali, M.R. (2011). The role of kras mutations and MSI status in diagnosis of colorectal cancer. Gastroenterology and Hepatology from bed to bench 4, 70.</li>
<li class="show">Sobhani, S., GHAFFARPOUR, M., MOSTAKHDEMIN, H.Z., Kamali, F., NOUR, M.Z., and HOUSHMAND, M. (2010). The prevalence of common mutation frequency in K-ras codons 12, 13 in Iranian Colorectal Cancer patients.</li>
<li class="show">Symvoulakis, E., Zaravinos, A., Panutsopulos, D., Zoras, O., Papalambros, E., Sigala, F., and Spandidos, D. (2007). Highly conserved sequence of exon 15 BRAF gene and KRAS codon 12 mutation among Greek patients with colorectal cancer. International Journal of Biological Markers 22, 12.&nbsp;<a href="https://doi.org/10.5301/JBM.2008.1785">https://doi.org/10.5301/JBM.2008.1785</a></li>
<li class="show">Tameshkel, F.S., Sohrabi, M.R., Reza, M., Babaee, H.R., Bahar, B., Imanzade, F., Zamani, F., Khonsari, M.R., Ajdarkosh, H., and Hemmasi, G. (2016). Mutation analysis of KRAS and BRAF genes in metastatic colorectal cancer: a first large scale study from Iran. Asian Pacific Journal of Cancer Prevention 17, 603-608.&nbsp;<a href="https://doi.org/10.7314/APJCP.2016.17.2.603">https://doi.org/10.7314/APJCP.2016.17.2.603</a></li>
<li class="show">Vakil, L., Najafipour, R., Rakhshani, N., Zamani, F., Morakabati, A., and Javadi, A. (2016). Investigation of FIH-1 and SOCS3 expression in KRAS mutant and wild-type patients with colorectal cancer. Tumor Biology 37, 8841-8848. <a href="https://doi.org/10.1007/s13277-015-4723-1">https://doi.org/10.1007/s13277-015-4723-1</a></li>
</ol>

Published

2017-10-16

Issue

Section

Review

How to Cite

The prevalence of KRAS mutation in colorectal cancer patients in Iranian population: A systematic review and meta-analysis study. (2017). Biomedical Research and Therapy, 4(10), 1693-1704. https://doi.org/10.15419/bmrat.v4i10.374

Similar Articles

321-330 of 442

You may also start an advanced similarity search for this article.